
Aerie Pharmaceuticals
Innovative ophthalmic therapies for glaucoma, dry eye, and retinal diseases.
Market cap
$754m
Enterprise value
$918m
Share price
$15.25 AERI
Authorizing premium user...
Innovative ophthalmic therapies for glaucoma, dry eye, and retinal diseases.